| Pharmaceuticals Industry | Healthcare Sector | Mr. Umang Vohra B.E., M.B.A. CEO | MSE Exchange | INE059A01026 ISIN |
| India Country | 27,764 Employees | 5 Jun 2026 Last Dividend | 24 Apr 2006 Last Split | - IPO Date |
Cipla Limited is a comprehensive pharmaceutical company established in 1935, with a primary focus on manufacturing, development, sale, and distribution of pharmaceutical products. With its headquarters in Mumbai, India, Cipla has expanded its reach internationally, actively operating in the United States, South Africa, and various other global markets. The company's business operations are segmented into Pharmaceuticals and New Ventures, highlighting its diverse interest in the healthcare and pharmaceutical industry. Cipla's commitment to healthcare is evident through its extensive range of products and involvement in consumer healthcare, biosimilars, and specialty businesses, aiming to address a broad spectrum of therapeutic areas and medical needs globally.
Cipla offers a comprehensive portfolio of generic and branded generic medicines, making essential drugs more accessible and affordable to the global population. These medicines cover a wide range of therapeutic areas, including but not limited to cardiovascular diseases, respiratory conditions, and diabetes management.
The company contributes to public health by providing vaccines, which are crucial for preventing infectious diseases and promoting health and wellness across various communities around the world.
Cipla manufactures and supplies high-quality active pharmaceutical ingredients, serving as the backbone for producing effective and safe medications. These APIs are critical for the development of a wide array of pharmaceutical products.
With expertise in pharmaceutical formulation, Cipla develops and distributes a range of formulations designed to treat numerous health conditions effectively, from chronic diseases like Alzheimer's and heart disease to acute conditions such as infections and critical care needs.
Beyond prescription medicines, Cipla is also involved in the consumer healthcare sector, offering over-the-counter (OTC) products that address everyday health concerns, including nutritional supplements and personal care items.
Investing in the future of biologic medicines, Cipla engages in the development and distribution of biosimilars. These products offer similar efficacy to original biologics, providing more affordable treatment options for patients.
Focusing on niche therapeutic areas, Cipla's specialty businesses concentrate on developing and commercializing advanced treatments for complex conditions, such as oncology and neuro psychiatry, underscoring the company's dedication to tackling challenging healthcare issues.